Recent in vitro studies showing increased sensitization of cancers with defects in DNA homologous recombination (as seen in BRCA1/2 deficient cancers), to PARP inhibition by targeting of PIK3CA [18,50] suggest that PIK3CA/mTOR pathway interactions result in homologous recombination steady state. The gene discussed is BRCA1; the disease is cancer.